Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a very poor patient prognosis (5-year survival of ≤ 7%). While transcriptional profiling has aided in the classification of this disease into at least two broader subtypes, this alone has so far been insufficient to inform on more nuanced patterns of oncogenic dependency. We hypothesized that a more comprehensive and granular characterization of PDAC disease diversity is required to establish relevant context for targeted therapy. To this end, we sought to establish an integrated platform to: i) more comprehensively characterize differential oncogenic signaling across our tumor models, and ii) establish a disease-specific co-expression network to delineate transc...
Pancreatic ductal adenocarcinoma (PDAC) can be divided into transcriptomic subtypes with two broad l...
Comprehensive molecular landscaping studies reveal a potentially brighter future for pancreatic duct...
Pancreatic ductal adenocarcinoma (PDAC) can be divided into transcriptomic subtypes with two broad l...
We performed integrated genomic, transcriptomic, and proteomic profiling of 150 pancreatic ductal ad...
We performed integrated genomic, transcriptomic, and proteomic profiling of 150 pancreatic ductal ad...
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest human malignancies. Surgery, the only...
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest human malignancies. Surgery, the only...
With a five-year survival rate of 9%, pancreatic ductal adenocarcinoma (PDAC) has the one of the wor...
With a five-year survival rate of 9%, pancreatic ductal adenocarcinoma (PDAC) has the one of the wor...
With a five-year survival rate of 9%, pancreatic ductal adenocarcinoma (PDAC) has the one of the wor...
Outcomes for patients with pancreatic ductal adenocarcinoma (PDAC) remain poor. Advances in next-gen...
PhD Theses MedicalPancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive and le...
Pancreatic ductal adenocarcinoma (PDAC) harbors the worst prognosis of any common solid tumor, and m...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer and the fourth leading cause of canc...
Pancreatic ductal adenocarcinoma (PDAC) is the most common malignancy of the pancreas and has one of...
Pancreatic ductal adenocarcinoma (PDAC) can be divided into transcriptomic subtypes with two broad l...
Comprehensive molecular landscaping studies reveal a potentially brighter future for pancreatic duct...
Pancreatic ductal adenocarcinoma (PDAC) can be divided into transcriptomic subtypes with two broad l...
We performed integrated genomic, transcriptomic, and proteomic profiling of 150 pancreatic ductal ad...
We performed integrated genomic, transcriptomic, and proteomic profiling of 150 pancreatic ductal ad...
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest human malignancies. Surgery, the only...
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest human malignancies. Surgery, the only...
With a five-year survival rate of 9%, pancreatic ductal adenocarcinoma (PDAC) has the one of the wor...
With a five-year survival rate of 9%, pancreatic ductal adenocarcinoma (PDAC) has the one of the wor...
With a five-year survival rate of 9%, pancreatic ductal adenocarcinoma (PDAC) has the one of the wor...
Outcomes for patients with pancreatic ductal adenocarcinoma (PDAC) remain poor. Advances in next-gen...
PhD Theses MedicalPancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive and le...
Pancreatic ductal adenocarcinoma (PDAC) harbors the worst prognosis of any common solid tumor, and m...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer and the fourth leading cause of canc...
Pancreatic ductal adenocarcinoma (PDAC) is the most common malignancy of the pancreas and has one of...
Pancreatic ductal adenocarcinoma (PDAC) can be divided into transcriptomic subtypes with two broad l...
Comprehensive molecular landscaping studies reveal a potentially brighter future for pancreatic duct...
Pancreatic ductal adenocarcinoma (PDAC) can be divided into transcriptomic subtypes with two broad l...